Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis

Metastasis of cancer cells from the primary tumor to other organs and tissues in the body is the leading cause of death in patients with malignancies. One of the principal ways cancer cells travel is through lymphatic vessels, and tumor invasion into the regional lymph nodes is a hallmark of early m...

Full description

Bibliographic Details
Main Authors: Chuqi Wang, Ming Chu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.783309/full
_version_ 1819364922056769536
author Chuqi Wang
Chuqi Wang
Ming Chu
author_facet Chuqi Wang
Chuqi Wang
Ming Chu
author_sort Chuqi Wang
collection DOAJ
description Metastasis of cancer cells from the primary tumor to other organs and tissues in the body is the leading cause of death in patients with malignancies. One of the principal ways cancer cells travel is through lymphatic vessels, and tumor invasion into the regional lymph nodes is a hallmark of early metastasis; thus, the formation of especially peritumoral lymphatic vessels is essential for tumor transportation that gives rise to further progression. In the past few decades, tumor-induced lymphangiogenesis has been testified to its tight correlation with lymphatic metastasis and poor clinical outcomes in multiple types of human malignancies, which warrants novel potential therapeutic targets for cancer treatment. As the understanding of underlying molecular mechanisms has grown tremendously over the years, an inexorable march of anti-lymphangiogenic therapy also aroused terrific interest. As a result, a great number of drugs have entered clinical trials, and some of them exhibited predominant contributions in cancer management. Herein, this review provides an updated summary of the current advances in therapies preventing lymphatic metastasis and discusses the validity of different applications.
first_indexed 2024-12-24T23:06:38Z
format Article
id doaj.art-656f01add0e54274957291a78e0ba16f
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-12-24T23:06:38Z
publishDate 2022-01-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-656f01add0e54274957291a78e0ba16f2022-12-21T16:35:00ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-01-011110.3389/fonc.2021.783309783309Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and MetastasisChuqi Wang0Chuqi Wang1Ming Chu2Department of Immunology, School of Basic Medical Sciences, Peking University, National Health Commission (NHC) Key Laboratory of Medical Immunology (Peking University), Beijing, ChinaI.M. Sechenov First Moscow State Medical University, Moscow, RussiaDepartment of Immunology, School of Basic Medical Sciences, Peking University, National Health Commission (NHC) Key Laboratory of Medical Immunology (Peking University), Beijing, ChinaMetastasis of cancer cells from the primary tumor to other organs and tissues in the body is the leading cause of death in patients with malignancies. One of the principal ways cancer cells travel is through lymphatic vessels, and tumor invasion into the regional lymph nodes is a hallmark of early metastasis; thus, the formation of especially peritumoral lymphatic vessels is essential for tumor transportation that gives rise to further progression. In the past few decades, tumor-induced lymphangiogenesis has been testified to its tight correlation with lymphatic metastasis and poor clinical outcomes in multiple types of human malignancies, which warrants novel potential therapeutic targets for cancer treatment. As the understanding of underlying molecular mechanisms has grown tremendously over the years, an inexorable march of anti-lymphangiogenic therapy also aroused terrific interest. As a result, a great number of drugs have entered clinical trials, and some of them exhibited predominant contributions in cancer management. Herein, this review provides an updated summary of the current advances in therapies preventing lymphatic metastasis and discusses the validity of different applications.https://www.frontiersin.org/articles/10.3389/fonc.2021.783309/fulllymphangiogenesisVEGFR-2/-3VEGF-C/-Dmetastasistyrosine kinase inhibitorangiogenesis
spellingShingle Chuqi Wang
Chuqi Wang
Ming Chu
Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
Frontiers in Oncology
lymphangiogenesis
VEGFR-2/-3
VEGF-C/-D
metastasis
tyrosine kinase inhibitor
angiogenesis
title Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
title_full Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
title_fullStr Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
title_full_unstemmed Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
title_short Advances in Drugs Targeting Lymphangiogenesis for Preventing Tumor Progression and Metastasis
title_sort advances in drugs targeting lymphangiogenesis for preventing tumor progression and metastasis
topic lymphangiogenesis
VEGFR-2/-3
VEGF-C/-D
metastasis
tyrosine kinase inhibitor
angiogenesis
url https://www.frontiersin.org/articles/10.3389/fonc.2021.783309/full
work_keys_str_mv AT chuqiwang advancesindrugstargetinglymphangiogenesisforpreventingtumorprogressionandmetastasis
AT chuqiwang advancesindrugstargetinglymphangiogenesisforpreventingtumorprogressionandmetastasis
AT mingchu advancesindrugstargetinglymphangiogenesisforpreventingtumorprogressionandmetastasis